What is it about?

This paper provides an efficient means to site-specifically incorporate potent immunostimulatory TLR2 ligands (e.g. Pam2Cys, Pam3Cys and LCP) site-specifically onto recombinant protein antigens. We also demonstrate the utility of this system when combined with engineered polytopic recombinant proteins for eliciting antibodies capable of preventing infection with group A streptococcus, an important disease associated bacterium.

Featured Image

Why is it important?

Many protein antigens have been identified in the literature, however potent immunostimulatory adjuvants are needed for the successful use of these antigens in commercial vaccines. The conjugation of adjuvants to antigens ensures that all vaccine components reach the same cell, improving vaccine potency. Our technology also ensures that we produce a commercially viable, molecularly-defined vaccine, rather than a mixture of compounds.


This is an example of our laboratories core technology platform, allowing for the site-specific conjugation of various types of adjuvants onto recombinant protein antigens. This technology is applicable to vaccines targeting many different diseases, and ensures that we produce a defined vaccine.

Dr Peter Michael Moyle
University of Queensland

Read the Original

This page is a summary of: Site-Specific Incorporation of Three Toll-Like Receptor 2 Targeting Adjuvants into Semisynthetic, Molecularly Defined Nanoparticles: Application to Group A Streptococcal Vaccines, Bioconjugate Chemistry, May 2014, American Chemical Society (ACS), DOI: 10.1021/bc500108b.
You can read the full text:



The following have contributed to this page